All In Biotech

Investigational drug · Phase 2

LY188011

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neoplasms, Child, Adolescent.

Phase 2

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3,576

Any phase or sponsor naming "LY188011"

First trial start

2016

May 19, 2016

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "LY188011", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Neoplasms
  • Child
  • Adolescent
  • Biliary Tract Cancer
  • Metastatic Cancer
  • Advanced Cancer

Approved drugs for the same conditions: Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "LY188011" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 13 on PubMed

Also in development for Neoplasms

  • CetrelimabJNJ-63723283Phase 38 trials

    Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms

  • VT3989Phase 32 trials

    Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult

  • [177Lu]Lu-NeoBLutetium NeoB, [177Lu]-NeoBPhase 22 trials

    Novartis · Breast Cancer, Neoplasms

  • [68Ga]Ga-NeoBGallium NeoB, [68Ga]-NeoBPhase 22 trials

    Novartis · Breast Cancer, Neoplasms

  • Checkpoint InhibitorPhase 22 trials

    EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms

  • AdAPT-001Phase 21 trial

    EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms

  • CORT125236NenocorilantPhase 21 trial

    Corcept Therapeutics · Neoplasms

  • E7386Phase 21 trial

    Eisai · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.